Browsing by Subject "FAERS"
Now showing items 1-4 of 4
-
Association of GLP-1 receptor agonists and risk of pancreatitis: a pharmacovigilance study based on FAERS database
(Brac University, 2023-03)GLP-1 Receptor Agonists (GLP-1 RAs) are a choice of antidiabetic drugs in the management of Type-2 Diabetes Mellitus (T2DM). Currently, there are five classes of GLP-1 RA drugs available in the market, all of which are ... -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
(Brac University, 2023-02)FDA has approved about 12 biologics for treating psoriasis. Among them, TNF-α inhibitors have a history of causing alopecia while used for treatment. In our study, we tried to find out the relation between alopecia and the ... -
Relationship between SGLT2 inhibitor use and risk of lower limb amputations: a pharmacovigilance study
(Brac University, 2023-03)Type 2 Diabetes Mellitus is a chronic, complicated, multifactorial condition affecting millions of people worldwide. A variety of anti-diabetic pharmacological interventions are available for the condition. Amongst many ... -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
(Brac University, 2023-02)The objective of this study was to investigate the association between TNF-alpha inhibitors and alopecia cases in psoriasis patients reported in the Food and Drug Administration Adverse Event Reporting System (FAERS) ...
